Table 1.
Proteogenomics profiling of the expression of complement and complement-related components in patients with lung cancer
| Type | Gene symbol | mRNA level | Protein level | Protein level |
|---|---|---|---|---|
| in tissue | in tissue | in serum | ||
| Activators | ||||
| C1s | − 2.20 ± 0.76 | − 2.15 ± 0.88 | 1.76 ± 0.77 | |
| C1r | − 2.57 ± 1.02 | − 4.4 | 2.10 ± 0.14 | |
| C1QA | − 1.83 ± 0.53 | − 1.84 ± 0.23 | 2.1 | |
| Early | C1QB | − 1.69 ± 0.64 | − 3.01 ± 0.79 | 0.87 |
| C1QC | − 1.65 ± 0.51 | − 2.06 ± 2.11 | NA | |
| C2 | − 1.40 ± 0.75 | − 1.17 | 1.40 ± 0.3 | |
| C4/C4a, b, d | − 2.20 ± 0.18 | − 1.94 ± 0.1 | 1.33 ± 0.36 | |
| ●MASP1 | − 1.5 | NA | NA | |
| CFD | −2.38 ± 0.72 | NA | NA | |
| Middle | CFP | −2.29 ± 0.86 | NA | NA |
| CFB | 1.52 ± 0.16 | −2.23 ± 1.26 | 3.17 ± 1.37 | |
| C3/C3c, b | − 3.65 ± 182 | −3.09 ± 1.17 | 2.19 ± 1.25 | |
| C5 | − 1.59 ± 0.43 | − 1.31 ± 0.3 | 2.00 ± 1.73 | |
| C6 | −3.74 ± 2.58 | − 1.50 ± 0.15 | 2.78 ± 2.23 | |
| C7 | −2.30 ± 0.99 | −2.05 ± 0.65 | 2.85 ± 0.95 | |
| Late | C8A | −0.2 | − 1.97 ± 0.45 | 5.58 |
| C8B | −2.26 ± 1.77 | − 1.89 | 5.01 | |
| C8G | 3.7 | −1.17 | 3.50 | |
| C9 | 5.05 | −1.27 ± 0.23 | 2.60 ± 1.33 | |
| Inhibitors | ||||
| C1NH | −2.11 ± 1.04 | −1.86 ± 0.21 | 2.23 ± 1.17 | |
| C1QBP | 1.77 ± 0.59 | 1.14 ± 0.64 | NA | |
| CFI | −1.70 ± 0.44 | −1.34 ± 0.62 | 2.51 ± 0.84 | |
| C4BPA | −4.00 ± 2.70 | −1.76 ± 0.74 | 2.08 ± 0.75 | |
| Secreted | C4BPB | − 1.42 ± 2.92 | −1 | NA |
| CFH | −1.91 ± 0.98 | −0.95 ± 0.21 | 4 | |
| CLU | −1.83 ± 0.58 | − 1.76 ± 0.37 | 3.04 ± 0.83 | |
| VTN | 3.1 | − 1.44 ± 0.62 | 3.24 | |
| VWF | −2.25 ± 0.73 | −2.27 ± 1.06 | NA | |
| SERPINA1 | −5.25 ± 1.77 | − 2.01 ± 0.41 | NA | |
| SERPINA3 | − 1.37 ± 0.71 | −1.69 ± 0.16 | 2.34 | |
| CD55/DAF | − 2.27 ± 1.02 | −2.47 ± 0.43 | NA | |
| CD59/MAC | −1.35 ± 0.40 | − 0.97 ± 0.36 | NA | |
| CD44 | −1.84 ± 0.81 | −1 | 2.66 | |
| CD46/MCP | 1.80 ± 0.14 | NA | 3 | |
| CD35/CR1 | −1.48 ± 0.22 | NA | NA | |
| CD21/CR2 | 2.07 ± 1.56 | NA | NA | |
| Membrane | ITGAM/CR3 | −2.67 ± 0.55 | 1.77 | NA |
| ITGAX/CR4 | −2.4 | NA | NA | |
| ITGB2/ CR3 | −2.20 ± 0.46 | NA | NA | |
| MRC1 | −2.15 ± 0.99 | −2.10 ± 1.22 | 1.27 ± 0.36 | |
| C3AR1 | −1.76 ± 0.92 | NA | NA | |
| CD88/C5AR1 | −1.84 ± 0.66 | UP | NA | |
| VSIG4/C3bR | −1.96 ± 0.69 | NA | NA | |
| CD93/C1QR1 | −1.97 ± 0.53 | −2.76 ± 0.93 | NA | |
| Regulators | ||||
| APOA1 | −0.52 | −2.98 ± 1.35 | 1.71 ± 0.23 | |
| APOA2 | −1.7 | −2.64 ± 0.54 | 1.46 | |
| APOA4 | NA | −1.10 ± 0.29 | 2.40 ± 0.99 | |
| APOB | NA | −1.71 ± 0.79 | 3.16 ± 2.74 | |
| APOC1 | −2.11 ± 0.88 | −2.19 ± 0.60 | 1.32 | |
| APOC2 | −1.04 | −2.87 ± 0.14 | NA | |
| APOC3 | NA | −2.07 ± 0.52 | 0.4 | |
| APOD | −1.90 ± 0.80 | −1.28 ± 0.45 | NA | |
| APOE | −2.00 ± 0.85 | − 1.15 ± 0.61 | 1.16 ± 0.18 | |
| APOL3 | −1.88 ± 1.11 | NA | NA | |
| A2M | −2.04 ± 0.99 | −2.63 | 2.43 ± 0.39 | |
| SERPINB1 | −2.78 ± 1.30 | NA | NA | |
| SERPINB2 | 4.35 ± 3.34 | 5.67 | NA | |
| SERPINB5 | 3.73 ± 3.05 | 3.74 | NA | |
| SERPIND1 | 1.73 ± 0.24 | −2.43 ± 1.25 | NA | |
| SERPINF1 | −1.70 ± 0.00 | −0.2 | NA | |
| SERPINH1 | 1.30 ± 0.20 | 2.36 ± 0.09 | NA | |
| SERPINI1 | 3.95 ± 1.46 | NA | NA | |
| SERBP1 | 1.20 ± 0.00 | 1.47 ± 0.71 | NA |
Notes: The levels of mRNA and proteins were calculated by using the log2 of Mean ± SD. All values represent lung cancer group versus the healthy controls. Complement-related components were indicated by italic letters to distinguish from complement components. Blue letters indicated that the change of these complement proteins were also detected in the current iTRAQ proteomic study. CFB, C8G, C9, VTN, ITGAM/CR3, CD88/C5AR1 and SERPIND1 with opposite tendency between mRNA and protein levels were indicated by red letter. NA: No data available. According to the reference, genes lacking specific ratio were indicated by “up” or “down” according to reference papers